March 2006 • Vol 52 • No 3
|
 |
| Features |
|
|
 |
Emerging Treatments for Diabetes Mellitus Type 1 or Type 2: Recently Approved Medications and More in the Pipeline |
| |
With self-assessment test |
| |
by Peter Emerson, MD, and James V. Felicetta, MD, Carl T. Hayden VA Medical Center, Banner Good Samaritan Medical Center, Phoenix, Ariz |
| |
The new modes of insulin administration and the new classes of diabetes medications, each with unique properties, may enhance patient compliance and improve glycemic control. |
|
|
|
The Clinical Features of Cluster Headache: Differential Diagnosis and Treatment Recommendations |
| |
With self-assessment test |
| |
by Sajan Thomas, MD, and Deepika Kanupuru, MD, Westlake Hospital, Melrose Park, Ill |
| |
Recognizing the characteristics of this debilitating pain syndrome and choosing appropriate medical therapy still present clinical challenges. |
|
|
|
Yersinia Pestis: New Challenges in the Age of Bioterrorism |
| |
With self-assessment test |
| |
by Marc A. Bellazzini, MD, University of Wisconsin Hospital & Clinics, Madison, and Michael Myint, MD, University of Washington Medical Center, Seattle |
| |
Still endemic to many parts of the country, the possibility of its use in warfare brings new urgency to this plague-causing bacterium. |
|
|
| |
Case Report & Commentary |
|
Dysphagia Aortica in an Elderly Woman |
| |
by Anayochukwu Uche, MD, University of Maryland, Baltimore, Md, and Sajan Thomas, MD, Westlake Hospital, Melrose Park, Ill. Commentary by Gregg S. Gagliardi, MD, and Sidney Cohen, MD, Thomas Jefferson University Hospital, Philadelphia, Pa |
| |
With the aging of the American population and the increased risk of vascular disease associated with aging, this uncommon disorder is likely to become more prevalent. |
|
|
|
Nonalcoholic Fatty Liver Disease, Insulin Resistance, and Metabolic Syndrome: one Disease Entity |
| |
by Christine Pocha, MD, PhD, Stratton VA Medical Center, Albany, NY |
| |
The author proposes that all patients with the metabolic syndrome or insulin resistance be screened for fatty liver disease, which could lead to cirrhosis or liver cancer. |
|
|
|
|
|
|
|
|
|
| Departments |
|
|
|
|
|
 |
|
Search
Resources
